In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 14, No. 652 ( 2022-07-06)
Abstract:
Loss of BRCA1 or BRCA2 (BRCA) activity is common in triple-negative breast cancer (TNBC) and ovarian cancer (OvCa); however, the type of alteration can result in different treatment responses. Here, Menghi et al . examined the differences in response to platinum therapy of patients with TNBC and OvCa who had BRCA loss or genetic alterations as compared to promotor methylation of BRCA. They saw that both patients and mice with promotor methylation were able to adaptively lose methylation, gain BRCA1 expression, and acquire resistance to platinum therapy. These findings have broad implications in using BRCA alteration status to better predict patient.
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abn1926
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2022
Permalink